A Phase 1/3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (NCT05473910)
A Phase 1/3 Study Evaluating the Efficacy and Safety of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA-2)
🩺 Plain-English Summary (8th-Grade Level)
This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminary efficacy of an escalating dose regimen of up to 2 doses of TSC-100 and TSC-101 in patients with AML, MDS, or ALL following HCT from a haploidentical donor, MMUD, or MUD
Who can join: Review the eligibility criteria below.
Location: City of Hope — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (21 Sites)
- City of Hope — Duarte, California
- University of Colorado - Anschutz Cancer Center — Aurora, Colorado
- SCRI - Colorado Blood Cancer Institute — Denver, Colorado
- Yale — New Haven, Connecticut
- Memorial Cancer Institute — Hollywood, Florida
- Moffitt Cancer Institute — Tampa, Florida
- Northside Hospital — Atlanta, Georgia
- Johns Hopkins University — Baltimore, Maryland
- Mass General Hospital — Boston, Massachusetts
- Dana-Farber Cancer Institute - Hematology/Oncology — Boston, Massachusetts
- Karmanos Cancer Institute — Detroit, Michigan
- Hackensack University Medical Center — Hackensack, New Jersey
- Columbia University — New York, New York
- Mount Sinai — New York, New York
- University North Carolina — Chapel Hill, North Carolina
- University of Pennsylvania — Philadelphia, Pennsylvania
- SCRI - TriStar Bone Marrow Transplant — Nashville, Tennessee
- St. David's South Austin Medical Center — Austin, Texas
- Baylor University Medical Center — Dallas, Texas
- MD Anderson — Houston, Texas
- Froedert and Medical College of Wisconsin — Milwaukee, Wisconsin
📞 Contact the Study Coordinator
Phone: (857) 399-9500
Email: medicalaffairs@tscan.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in AML
- ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial — Houston, Texas
- A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant — Rochester, New York
- A Long Term Follow-up Study of TScan TCR-T Products — Duarte, California
- CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF) — Sacramento, California
- Cardioprotection in AML — Charlottesville, Virginia
- UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy — Birmingham, Alabama
Explore by condition: All AML clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.